|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||8.02 - 8.02|
|52 Week Range||2.98 - 13.90|
|Beta (3Y Monthly)||-2.91|
|PE Ratio (TTM)||4.20|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
IRVINE, CA, Feb. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – TRIMEDYNE, INC. (OTCPINK “TMED”) today reported its financial results for its quarter ending on December 31, 2018. For the Quarter Ended December 31, 2018, Trimedyne had revenues of $1,188,000, a decrease of 23% from revenues of $1,534,000 for the prior year quarter. As a result of this decrease, we had a net loss for the current quarter of $31,000 or $0.25 per share, as compared to net income of $86,000 or $0.70 per share for the prior year quarter. Commenting on the financial results for the quarter, Marvin P. Loeb, Sc.D., Chairman of Trimedyne, said: “Since we are no longer required to file periodic reports with the SEC, our Financial Statements are un-audited. However, we believe our Financial Statements have been prepared and contain all adjustments of a recurring nature that are necessary for a fair presentation of our operations and financial condition for the period and dates shown in the financial statements attached herein.
Irvine, California, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- TRIMEDYNE, INC. (OTCBB “TMED”) today reported its financial results for its Fiscal Year ending on September 30, 2018. For the Fiscal Year Ended September 30, 2018, Trimedyne had revenues of $5,567,000, an increase of 18.6% from revenues of $4,695,000 for the prior year. We had net income for the current year of $234,000 or $1.91 per share, as compared to a net loss of $44,000 or $0.36 per share for the prior year, adjusted for a 150 to one reverse stock split in November, 2016. This $278,000 increase compared to the prior fiscal year is a considerable improvement, which was primarily the result of the increase in sales stated above.